Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 82Carcinoma, Non-Small-Cell Lung 72Carcinoma, Renal Cell 42Neoplasm Metastasis 31Neoplasms 29Squamous Cell Carcinoma of Head and Neck 26Lung Neoplasms 25Colorectal Neoplasms 23Carcinoma, Hepatocellular 20Hodgkin Disease 18Small Cell Lung Carcinoma 17Prostatic Neoplasms 14Carcinoma, Transitional Cell 13Head and Neck Neoplasms 12Urinary Bladder Neoplasms 11Pancreatic Neoplasms 11Ovarian Neoplasms 11Multiple Myeloma 11Advanced Cancer 11Triple Negative Breast Neoplasms 10Lymphoma 10Glioblastoma 10Kidney Neoplasms 9Breast Neoplasms 9Recurrence 8Lymphoma, Non-Hodgkin 8Leukemia, Myeloid, Acute 8Glioma 8Stomach Neoplasms 7Myelodysplastic Syndromes 7

Interventions

trastuzumab deruxtecan 1omburtamab I-131 1merphos 1epothilone B 1adavosertib 1XL647 1Transplantation, Autologous 1Sorafenib 1Rituximab 1Radiotherapy 1Radiation 1Nivolumab 1Methotrexate 1Ipilimumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Meningeal Carcinomatosis × Nivolumab × Clear all
NCT02939300 2025-11-14

Ipilimumab and Nivolumab in Leptomeningeal Metastases

Massachusetts General Hospital

Phase 2 Completed
18 enrolled 17 charts
CNS

Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡